A Phase I, Open-label, Single-dose, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of the UB-421 Antibody in Asymptomatic HIV-1 Infected Adults.

Trial Profile

A Phase I, Open-label, Single-dose, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of the UB-421 Antibody in Asymptomatic HIV-1 Infected Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2011

At a glance

  • Drugs UB 421 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Jul 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 08 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top